PS230005 Control-IQ 1.5 Post-Approval Study

Más betegség

• A medical or other condition, or medications being taken that in the investigator's judgement would be a safety concern for participation in the study.

Laborértékek

• Use of any glucose-lowering therapy other than insulin.

• Self-reported type 1 diabetes who have been prescribed the Control-IQ 1.5 system in the t:slim X2 or Mobi insulin pump
• Age 2 to <6 years at time of screening
• Using an insulin approved for use in the pump
• Using an iCGM sensor approved for use with the pump
• Agreement to use Control-IQ technology 1.5, and to continue use for at least 12 consecutive months after study enrollment.
• Agree to provide HbA1c result, obtained within the 6-month period prior to enrollment.
• Ability for parent/guardian to respond to alerts and alarms, and to provide basic diabetes self-management.
• Reside full-time in the United States.
• Willingness to download the t:connect Mobile application to their smartphone and keep it active throughout the study if using a Tandem t:slim X2 pump. Participants who are unable to use the t:connect mobile application must be willing to manually upload their insulin pump data to Tandem Source every three months and at the completion of the study.
• Participant's parent/guardian has read, understood and agreed to participate in the study, and has electronically signed the Informed Consent Form (ICF).